Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

240 questions · 244 findings · 23 reviews

No studies found 39 · 16%GRADE not reported 15 · 6.1%Very low 78 · 32%Low 52 · 21.3%Moderate 49 · 20.1%High 11 · 4.5%

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with atypical agent (low certainty).

1 finding from 1 review

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with atypical agent (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Mental state: PANSS responders (ITT data) ‐ medium term PANSS responders‐ participants achieving a >30% improvement in total score · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in mental state: PANSS responders (ITT data) ‐ medium term PANSS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Movement disorder requiring the use of anti‐EPS medication ‐ medium term · patients with schizophrenia

RISPERIDONE DEPOT probably leads to higher adverse events: Movement disorder requiring the use of anti‐EPS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Any prolactin‐related ‐ medium term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Any prolactin‐related ‐ medium term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Any glucose‐related ‐ medium/long term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

1 finding from 1 review

Pericyazine vs atypical antipsychotics

Leaving the study early for specific reasons · patients with schizophrenia

It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine vs atypical antipsychotics

Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia

It is very uncertain whether pericyazine changes global state ‐ not improved compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine vs atypical antipsychotics

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether pericyazine changes adverse Effects ‐ Extrapyramidal symptoms compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Weight: 2a. BMI ‐ Increase · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes weight: 2a. BMI ‐ Increase compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Physiological measures: 1c. Average fasting glucose change ‐ switching to aripiprazole and quetiapine · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review